---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-120724"
form_type: "8-K"
ticker: "LABT"
cik: "0002079272"
company_name: "Lakewood-Amedex Biotherapeutics Inc."
filed_at: "2026-11-16T21:35:47+00:00"
generated_at: "2026-11-16T21:41:59.989384+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Nasdaq to delist Lakewood-Amedex (LABT) after 30 days below $1.00; hearing sought

## Summary
- Nov 10, 2026 Nasdaq staff letter: closing bid price stayed below $1.00 for 30 consecutive business days, Sept 29 through Nov 9, 2026.
- Company is not eligible for a compliance cure period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year.
- Unless a hearing is requested by Nov 17, 2026, trading is suspended at the open on Nov 19, 2026 and Nasdaq files Form 25-NSE to delist.
- Company says it intends to timely request a Nasdaq Hearings Panel hearing, which would stay suspension, and may propose another reverse split.
- Company warns no assurance the Panel grants continued listing or that it regains compliance with Rule 5550(a)(2).

## SEC filing metadata
- accession: 0001213900-26-120724
- form_type: 8-K
- ticker: LABT
- cik: 0002079272
- company_name: Lakewood-Amedex Biotherapeutics Inc.
- filed_at: 2026-11-16T21:35:47+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026120724/0001213900-26-120724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2079272/000121390026120724/ea0312471-8k_lakewood.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-120724
- JSON: https://secwatch.observer/filing/0001213900-26-120724.json
- Plain text: https://secwatch.observer/filing/0001213900-26-120724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
